Evidence map›Paper›PMID 37750173›Full record

ArticleInfection and drug resistance2023

Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA.

Xuejiao Liao, Yuan Guan, Tetsuya Asakawa, Zixun Lin, Qingrong Tang, Zhenghua Ma, Shuting Wu, Xiaobin Wang, Jingke Dong, Liping Zhang and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Xuejiao Liao *Institute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Yuan Guan *Institute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Tetsuya Asakawa *Institute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.ORCID 0000-0002-2300-3509
Zixun LinInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Qingrong TangThe First Hospital of Changsha, Infectious Diseases Department, Changsha, People's Republic of China.
Zhenghua MaInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Shuting WuInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Xiaobin WangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Jingke DongInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Liping ZhangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Jiayu DengInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Zhonghui LiaoInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Sumei YangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Cheng WangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Shuo SongInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Hongyang YiInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Song WuDepartment of Central Laboratory, South China Hospital, Medical School, Shenzhen University, Shenzhen, People's Republic of China.ORCID 0000-0003-3504-1630
Hongzhou LuInstitute for Hepatology, National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.ORCID 0000-0002-8308-5534
Southern University of Science and Technology · CNBengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose was to review relevant clinical data and formulate recommendations supporting the use of saline as a simple rinse for an early reassuring intervention to reduce the occurrence of re-positive COVID-19 patients. Methods: We conducted a single-centre retrospective cohort study, which enrolled patients with confirmed re-testing positive COVID-19 during 7-60 days after discharge from Third People's Hospital of Shenzhen. By one-to-two propensity score matching for age and sex, the control group of those not re-testing positive during the same period served as matched control. Results: A total of 223 patients were included in our study, 94 in re-positive group and 129 in non-re-positive group. The result shows that the rates of nasal douche treatment in the non-re-positive group were considerably higher than that of the re-positive group. And the Ct value of nasal douche group increased faster than that of non-nasal douche group after the Ct value reaching ≥35. Further analysis revealed that the higher the Ct value at the time of readmission, the shorter the time of average Ct values to reach ≥35. Conclusion: These findings suggest that nasal douche is beneficial to shorten the time of virus nucleic acid turning negative, thereby reducing the incidence of re-positive. The prevention and control of epidemics focuses on re-positive patients with Ct values <35.

Indexed as

COVID-19nasal douchere-positiveRT-PCR

Identifiers

PMID37750173
PMCPMC10518237
OpenAlexW4386935820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.